Management of peritoneal-surface malignancy: the surgeon's role

Peritoneal surface malignancy can result from seeding of gastrointestinal cancer or abdominopelvic sarcoma; it can also occur as a primary disease, for example, peritoneal mesothelioma. In the past, this clinical situation was treated only with palliative intent. An aggressive approach to peritoneal...

Full description

Saved in:
Bibliographic Details
Published in:Langenbeck's archives of surgery 1999-12, Vol.384 (6), p.576-587
Main Author: Sugarbaker, P H
Format: Article
Language:English
Subjects:
Clinical Trials, Phase II as Topic
Ethics, Medical
Humans
Neoplasm Seeding
Palliative Care
Patient Selection
Peritoneal Neoplasms - drug therapy
Peritoneal Neoplasms - secondary
Peritoneal Neoplasms - surgery
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peritoneal surface malignancy can result from seeding of gastrointestinal cancer or abdominopelvic sarcoma; it can also occur as a primary disease, for example, peritoneal mesothelioma. In the past, this clinical situation was treated only with palliative intent. An aggressive approach to peritoneal surface malignancy involves peritonectomy procedures, perioperative intraperitoneal chemotherapy and knowledgeable patient selection. The clinical assessments necessary for valid clinical judgements include the cancer histopathology (invasive vs expansive progression), the preoperative abdominal and pelvic computed tomogram, the peritoneal cancer index and the completeness of cytoreduction score. Proper patient selection is mandatory for optimizing the results of treatment. In a series of phase-II studies, appendiceal tumors with peritoneal seeding was the paradigm for success with a 75% long-term survival in properly selected patients. Carcinomatosis from colon cancer had an overall 5-year survival of 20% but with selected patients this reached 50%. Also, sarcomatosis patients overall had only a 10% 5-year survival but selected patients had a 75% survival. In all malignancies, early aggressive treatment of minimal peritoneal surface dissemination showed the greatest benefit. The surgeon must accept responsibility for knowledgeable management of peritoneal surface dissemination of cancer. A curative approach has been demonstrated in large phase-II studies. Adjuvant studies with perioperative intraperitoneal chemotherapy in diseases where peritoneal surface spread occurs are indicated.
ISSN:1435-2443
1435-2451
DOI:10.1007/s004230050246